Immune restoration with antiretroviral therapies: Implications for clinical management

JAMA

Volumn 284, Issue 2, 2000, Pages 223-228

  Lederman, Michael M ^a,b   Valdez, Hernan ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

EID: 0034641205     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.2.223     Document Type: Article

References (84)

1. Chowdry TVH, Asaad R, Woolley I, et al.The changing spectrum of HIV mortality: 249 deaths from 1995-1999. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 463.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996;173:321-329.
4. + T-cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
5. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir. J Infect Dis. 1998;178:70-79.
6. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection. Nat Med. 1998;4:208-214.
7. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181:358-363.
8. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 1998;12: F123-F129.
9. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999;103:1391-1398.
10. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351:543-549.
11. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
12. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:318-326.
13. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998;351:1682-1686.
14. Mezzaroma I, Carlesimo M, Pinter E, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS. 1999;13:1187-1193.
15. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS. 1999;13:669-676.
16. Arno A, Ruiz L, Juan M, et al. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. AIDS. 1998;12:697-704.
17. Notermans DW, Pakker NC, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis. 1999;180:1050-1056.
18. + T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy. J Infect Dis. 1999;180:1057-1063.
19. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. AIDS. 2000;14:11-21.
20. + repertoire during antiviral therapy. Nat Med. 1998;4:215-221.
21. + T-cell repopulation kinetics during highly active antiretroviral therapy. AIDS. 1998;12:F235-F240.
22. + T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses. 1998;14:561-569.
23. Patki AH, Purvis SF, Valdez H, et al. HIV infection perturbs DNA content of lymphoid cells. AIDS. 1999;13:1177-1185.
24. Giorgi JV, Majchrowicz MA, Johnson TD, et al. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS. 1998; 12:1833-1844.
25. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. AIDS. 1998;12:2115-2123.
26. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998;102:79-87
27. Wu H, Kuritzkes DR, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1 -infected patients treated with combination antiretroviral therapy. J Infect Dis. 1999;179: 799-807.
28. Wu H, Kuritzkes D, Landay A, et al, and the ACTG 315 Team. Cell kinetic patterns and their relationships with virologic responses in HIV-1 infected patients treated with HAART. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 340.
29. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12:745-750.
30. Hill A, Montaner J, Lederman M, et al. Discordant CD4/RNA responses to HAART are strongly associated with high baseline CD4 count and low HIV RNA. From: 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract 152.
31. + T-cell responses after suppression of HIV replication may reflect thymic failure. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 327.
32. + cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2000;30:392-394.
33. Davey RT Jr, Chaitt DG, Piscitelli SC, etal. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis. 1997;175:781-789.
34. Katlama C, Chouquet C, Autran B, et al. ILSTIM (ANRS 082). From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 543.
35. Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1. J Infect Dis. 1999; 180:56-60.
36. Brites EA. Granulocyte macrophage colony stimulating factor (GM-CSF) reduces viral load and increases CD4 cell counts in individuals with AIDS receiving AZT. From: XII International Conference on AIDS; June 28-July 3, 1998; Geneva, Switzerland.
37. Deresinski SC. Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection. AIDS. 1999;13:633-643.
38. Kees UR, Ford J. Synergistic action of stem-cell factor and interleukin-7 in a human immature T-cell line. Immunology. 1999;96:202-206.
39. Okamoto Y, McFarland R, Koup R. Increasing thymic output with exogenous IL-7. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 326.
40. Patki AH, Quinones-Mateu ME, Dorazio D, et al. Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression. J Clin Invest. 1996;98:616-621.
41. Kanai T, Thomas EK, Yasutomi Y, Letvin NL. IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol. 1996;157:3681-3687.
42. Chehimi J, Marshall JD, Salvucci O, et al. IL-15 enhances immune functions during HIV infection. J Immunol. 1997;158:5978-5987.
43. Al-Harthi L, Roebuck KA, Landay A. Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15. J Clin Immunol. 1998;18:124-131.
44. + T cell responses associated with control of viremia. Science. 1997;278: 1447-1450.
45. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000;181:121-131.
46. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent antihuman immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898-904.
47. Al-Harthi L, Siegel J, Spritzler J, et al. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000;14:761-770.
48. Rosenberg E, Poon S, Wilkes B, et al. Generation and maintenance of HIV-specific T-helper cell responses in persons treated during acute HIV-1 infection and augmentation of these responses following structured treatment interruption. From: 37th Annual Meeting of the Infectious Diseases Society of America; November 18-21, 1999; Philadelphia, Pa. Abstract 725.
49. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995; 333:408-413.
50. Valentine F, and the Remune 816 Study Team. Immunological and virological evaluations of the effects of HAART compared to HAART plusan inactivated HIV-1 immunogen after 32 weeks. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-Febrary 4, 1999; Chicago, Ill. Abstract 346.
51. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression. Ann Intern Med. 1999; 130:570-577.
52. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic. AIDS. 1999;13:F35-F43.
53. Valdez H, Lederman MM, Woolley I, et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice. Arch Intern Med. 1999;159:1771-1776.
54. Miller V. Antiretroviral treatment on and off. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Diego, Calif. Abstract 2063.
55. Deeks S, Hoh R, Troiano J, et al. Virologic and immunologic evaluation of structured treatment interruption (STI) in patients experiencing long-term virologic failure. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-Febmary 2, 2000; San Francisco, Calif. Abstract LB10.
56. Wendland T, Furrer H, Vernazza PL, et al. HAART in HIV-infected patients. AIDS. 1999;13:1857-1862.
57. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 -infected adults treated with combination antiretroviral therapy. N Engl J Med. 1999; 340:1301-1306.
58. Mocroft A, Sabin CA, Youle M, et al. Changes in AIDS-defining illnesses in a London clinic, 1987-1998. J Acquir Immune Defic Syndr. 1999;21:401-407.
59. Weverling GJ, Mocroft A, Ledergerber B, et al, for the EuroSIDA Study Group. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infec-tion. Lancet. 1999;353:1293-1298.
60. Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. Ann Intern Med. 2000;132:201-205.
61. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med. 2000; 342:1085-1092.
62. Ledergerber B, Reiss P, Furrer HJ, et al. It is safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract LB5.
63. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med. 2000;342: 1416-1429.
64. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1999;48:1-66.
65. Aberg J A, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis. 1998;178:1446-1449.
66. Aberg J, Heeren D, Pearce R, Bredt B. Discontinuation of antifungal therapy for cryptococcosis after immunological response to antiretroviral therapy. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 250.
67. Miro J, Podzamczer D, Pena J, et al. Discontinuation of toxoplasmic encephalitis prophylaxis is safe in HIV-1 and Tgondii coinfected patients after immunological recovery with HAART. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-Febrtary 2, 2000; San Francisco, Calif. Abstract 230.
68. + counts. Ophthalmology. 1998;105:1259-1264.
69. Tural C, Romeu J, Sirera C, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis, 1998;177:1080-1083.
70. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999;282:1633-1637.
71. Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA. 2000; 283:653-657.
72. + T-cell responses in HIV-1-infected subjects with relapsing CMV retinitis following successful highly active antiretroviral therapy. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 580.
73. Johnson S, Johnson D, Weinberg A. Recurrent cytomegalovirus retinitis in a patient on highly active antiretroviral therapy despite apparent immune recon-stitution. From: 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, Calif. Abstract 272.
74. Canzano JC, Reed JB, Morse LS. Vitreomacular traction syndrome following highly active antiretroviral therapy in AIDS patients with cytomegalovirus retinitis. Retina. 1998;18:443-447.
75. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of success-ful highly active antiretroviral therapy. J Infect Dis. 1999;179:697-700.
76. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. 1998;351:252-255.
77. Jones JL, Hanson DL, Dworkin MS, et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S11-S17
78. Pezzotti P, Serraino D, Rezza G, et al. The spectrum of AIDS-defining diseases. Int J Epidemiol. 1999; 28:975-981.
79. Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr. 1999;21 (suppl 1):S31-S33.
80. Jacobson LP, Yamashita TE, Detels R, et al. Im-pact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S34-S41.
81. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy. BMJ. 1999; 319:23-24.
82. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998; 188:233-245.
83. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy. AIDS. 2000;14:F25-F32.
84. McGovern B, Stone D, Snydman D. Increasing mortality from end-stage liver disease secondary to hepatitis C in patients with human immunodeficiency virus infection. From: 37th Annual Meeting of the Infectious Diseases Society of America; November 18-21, 1999; Philadelphia, Pa. Abstract 235.